Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Diffuse alveolar damage associated with ticlopidine use: a case report.

Pei-Ching Oon1, Jih-Shuin Jerng, Hsien-Li Kao

  • 1Department of Internal Medicine, En Chu Kung Hospital, Taipei, Taiwan.

Journal of the Formosan Medical Association = Taiwan Yi Zhi
|July 2, 2003
PubMed
Summary

Ticlopidine can cause rare lung disease. A patient developed diffuse alveolar damage after ticlopidine treatment for heart issues, improving after medication withdrawal and steroids.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plain language summary of TASUKI-52: A study looking at nivolumab plus platinum chemotherapy and bevacizumab as a combined treatment for people with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC).

Future oncology (London, England)·2026
Same author

Four-Year Outcomes for Nivolumab With Chemotherapy and Bevacizumab in Patients With Nonsquamous NSCLC in the TASUKI-52.

Cancer science·2026
Same author

Coccidioidomycosis: an emerging disease in Taiwan.

Journal of the Formosan Medical Association = Taiwan yi zhi·2026
Same author

Comparative study of transbronchial cryobiopsy and transbronchial biopsy for diagnostic yield in peripheral pulmonary lesions.

Annals of medicine·2026
Same author

Effects of adjunctive corticosteroids therapy in Non-HIV Pneumocystis jirovecii pneumonia: a real-world multicenter cohort study.

Scientific reports·2025
Same author

Impact of dynapenia, presarcopenia and sarcopenia in chronic obstructive pulmonary disease: a prospective cohort study.

BMJ open respiratory research·2025

Area of Science:

  • Pulmonology
  • Cardiology
  • Pharmacology

Background:

  • Ticlopidine is an antiplatelet medication used after coronary artery stenting.
  • Acute myocardial infarction (AMI) is a serious cardiac event requiring intervention.
  • Ticlopidine-induced lung disease is a rare but serious adverse effect.

Observation:

  • A 52-year-old male with AMI developed respiratory distress two days post-ticlopidine initiation.
  • Chest imaging showed bilateral upper lung haziness, unresponsive to edema treatment.
  • Mechanical ventilation was required due to severe respiratory compromise.

Findings:

  • Open lung biopsy confirmed diffuse alveolar damage (DAD).
  • Pulmonary condition improved after ticlopidine discontinuation and corticosteroid therapy.

Related Experiment Videos

  • The patient was successfully weaned from mechanical ventilation within two weeks.

    • Implications:

    • Diffuse alveolar damage is a potential adverse effect of ticlopidine.
    • Consider ticlopidine-induced lung disease in patients with poor response to therapy.
    • Early recognition and withdrawal of ticlopidine are crucial for patient recovery.